Editor: What To Know
- Most recently, he was a key executive in the acquisition (to Boston Scientific Corporation) of Vertiflex, a privately held company focused on treating patients with spinal stenosis.
- “I’m glad to join PainTEQ and help develop the commercialization strategy of the LinQ System, an advancement providing positive clinical benefits for patients currently experiencing chronic pain from SI Joint dysfunction,”.
- PainTEQ is the creator of LinQ (pronounced “link”), a minimally invasive therapy for SI joint dysfunction.
PainTEQ, a leading medical device innovator, announced the appointment of Michael Enxing, Chief Commercial Officer of Boston Scientific Corporation, Neuromodulation Division. PainTEQ is the creator of LinQ (pronounced “link”), a minimally invasive therapy for SI joint dysfunction.
With nearly three decades of executive experience, Enxing provides commercial know-how and strategic insight for medical device businesses. Most recently, he was a key executive in the acquisition (to Boston Scientific Corporation) of Vertiflex, a privately held company focused on treating patients with spinal stenosis.
“I’m glad to join PainTEQ and help develop the commercialization strategy of the LinQ System, an advancement providing positive clinical benefits for patients currently experiencing chronic pain from SI Joint dysfunction,” said Enxing. “With innovative medical technologies like LinQ, we have an unprecedented opportunity to make meaningful long-term impact while improving quality of life.”
Enxing also worked as an executive with Nevro Corp, Cardiovascular Systems Incorporated, Vertos Medical, Tecnol, Stryker, and St. Jude Medical. Enxing’s deep and proven expertise encompasses peripheral, neuro, functional neuro, spine, pain, cardiology, and image-guided surgery markets.
“Michael contributes a wealth of experience backed by a long-successful track record,” said PainTEQ CEO Sean LaNeve. “His vast business acumen provides particular value to the board in the areas of strategic planning, pre/post-FDA development, marketing management, corporate launches, M&A, IPOs, and private investment.”
